Morita Norishige, Mandel William J, Kobayashi Yoshinori, Karagueuzian Hrayr S
Division of Cardiology, Department of Medicine, Tokai University Hachioji Hospital, Tokyo, Japan.
Translational Arrhythmia Research Section, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
J Arrhythm. 2014 Dec 1;30(6):389-394. doi: 10.1016/j.joa.2013.12.008.
Animal and emerging clinical studies have demonstrated that increased ventricular fibrosis in a setting of reduced repolarization reserve promotes early afterdepolarizations (EADs) and triggered activity that can initiate ventricular tachycardia and ventricular fibrillation (VT/VF). Increased ventricular fibrosis plays a key facilitatory role in allowing oxidative and metabolic stress-induced EADs to manifest as triggered activity causing VT/VF. The lack of such an arrhythmogenic effect by the same stressors in normal non-fibrotic hearts highlights the importance of fibrosis in the initiation of VT/VF. These findings suggest that antifibrotic therapy combined with therapy designed to increase ventricular repolarization reserve may act synergistically to reduce the risk of sudden cardiac death.
动物研究和新出现的临床研究表明,在复极储备降低的情况下,心室纤维化增加会促进早期后除极(EADs)和触发活动,进而引发室性心动过速和心室颤动(VT/VF)。心室纤维化增加在使氧化应激和代谢应激诱导的EADs表现为引发VT/VF的触发活动方面起关键促进作用。正常非纤维化心脏在相同应激源作用下未出现这种致心律失常效应,凸显了纤维化在VT/VF起始中的重要性。这些发现表明,抗纤维化治疗与旨在增加心室复极储备的治疗相结合,可能会协同作用以降低心源性猝死风险。